Michael Egan, Executive Director at Merck, to Present at CNS Diseases World Summit 2016

Boston, MA, July 21, 2016 --(PR.com)-- Michael Egan, Executive Director of Clinical Neuroscience at Merck, will give a featured presentation at GTCbio’s CNS Diseases World Summit 2016 to be held on September 12-15, 2016 in Boston, MA.

This meeting provides an interactive learning and relationship-building forum for all players in the CNS field. Colleagues from industry, academia, government agencies, and financing bodies will gather at the interface of research, partnerships, funding, and commercialization to find ways to move forward in a field that has been troubled with clinical failures.

The program will provide a comprehensive look at the current state of CNS, from research to commercialization. Above all, this event will provide networking opportunities in an intimate and accessible environment.

The CNS Diseases World Summit consists of two, back-to-back conferences:

10th Neurodegenerative Conditions Research & Development

Sessions include:

I. Neuroinflammation Across CNS Disorders
II. Advances in Parkinson’s Disease Research & Therapeutics
III. Advances in Genetics and Systems Biology
IV. Biomarkers: Translation from Discovery to Clinical
V. Novel Therapeutics & Approaches in Alzheimer’s Disease
VI. Rare and Orphan CNS Disorders

9th CNS Partnering & Deal-Making

Sessions include:

I. CNS: Present and Future
II. Partnering & Licensing in CNS
III. An Update on Neurodegeneration and the State of the Art
IV. What Sells Big Pharma in CNS
V. Partnering with Patient Groups to Advance Research
VI. Regulatory Considerations for Orphan Drug Products
VII. CNS Perspectives: Venture Capital and Public Markets

For more information, please visit website: www.gtcbio.com/conferences/cns-diseases-world-summit-overview

GTCbio
635 W. Foothill Blvd
Monrovia, CA 91016
www.gtcbio.com
Email: infogtcbio@gtcbio.com
Phone: (626) 256-6405
Fax: (626) 466-4433